Disrupted valine metabolism and SCPC-mediated neurological toxicity in ECHS1 deficiency
6 affiliations
- 1Graduate School of Biomedical Sciences, University of Texas Southwestern Medical Center, Dallas, TX, United States
- 2Center for Alzheimer’s and Neurodegenerative Diseases, University of Texas Southwestern Medical Center, Dallas, TX, United States
- 3Center for Human Nutrition, University of Texas Southwestern Medical Center, Dallas, TX, United States
- 4Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, United States
- 5Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX, United States
- 6Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX, United States
Abstract
Background: ECHS1 Deficiency (ECHS1D) is a rare neurometabolic disorder caused by loss of function in the mitochondrial enzyme short-chain enoyl-CoA hydratase (ECHS1), leading to developmental delay, dystonia, seizures, and early mortality. Impaired ECHS1 activity disrupts valine catabolism, resulting in accumulation of reactive valine-derived intermediates associated with disease severity, though direct experimental evidence of neuronal toxicity and therapeutic modifiability remains limited. This study aimed to define the consequences of impaired ECHS1 activity, focusing on valine-derived intermediates and their impact on neuronal mitochondrial function.
Methods: Wild-type and Echs1-deficient (Echs1D) mouse neuroblastoma (N2A) cells were utilized to investigate effects of patient-relevant valine intermediates S-(2-carboxypropyl)cysteine (SCPC), S-(2-carboxyethyl)cysteine (SCEC), and 2,3-dihydroxy-2-methylbutyric (DHMB) on mitochondrial function, oxidative stress, and cell viability. ECHS1D mice were used to quantify valine intermediates, evaluate pyruvate dehydrogenase complex (PDC) function, and assess seizure susceptibility under typical, excess, or restricted dietary valine intake.
Results: In wild-type N2A cells, SCPC exposure induced dose-dependent cell toxicity and impaired mitochondrial respiration, while SCEC and DHMB exerted distinct mitochondrial effects. In contrast, Echs1D N2A cells displayed preserved mitochondrial fitness with premature neuronal differentiation, indicating cell-type-specific metabolic adaptations. ECHS1D mice accumulated SCPC, which was exacerbated by excess dietary valine and associated with reduced pyruvate dehydrogenase complex activity, and worsened seizure susceptibility. Valine restriction initiated during adolescence failed to reduce SCPC or improve seizure outcomes and instead increased SCEC levels.
Conclusion: These studies demonstrate that accumulation of ECHS1D-specific valine intermediates, particularly SCPC, contributes to mitochondrial dysfunction and disease severity in ECHS1D. Dietary valine modulation during adolescence showed limited therapeutic benefit and induced broader metabolic perturbations, underscoring the need for improved therapeutic strategies.
Related
- Repurposing Cas12a2-mediated abortive infection for efficient and low-toxicity microbial genome editing
- Computational modelling of acetylcholine deficiency-mediated dysfunction in the basal ganglia-thalamocortical network related to Parkinson’s disease dementia
- N-WASP deficiency enhances oncogenic KRAS-mediated lung adenocarcinoma progression in mice
- Gut Microbiota-Mediated SN-38G Metabolism In Vitro: Effects of Murraya koenigii and Ruta graveolens
- P2Y receptor-mediated regulation of lipolysis, lipid droplet dynamics, and energy metabolism in podocytes
BibTeX
@article{eller2026disrupted,
title = {{Disrupted valine metabolism and SCPC-mediated neurological toxicity in ECHS1 deficiency}},
author = {Meghan M. Eller and Madison A. Bunce and Mamta Verma and Raegan M. Adams and Xiaorong Fu and Alina P. Montalbano and Felix Nitschke and Shawn C. Burgess and Rachel M. Bailey},
journal = {Frontiers in Molecular Biosciences},
year = {2026},
month = oct,
doi = {10.3389/fmolb.2026.1861051},
url = {https://doi.org/10.3389/fmolb.2026.1861051},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Disrupted valine metabolism and SCPC-mediated neurological toxicity in ECHS1 deficiency
AU - Meghan M. Eller
AU - Madison A. Bunce
AU - Mamta Verma
AU - Raegan M. Adams
AU - Xiaorong Fu
AU - Alina P. Montalbano
AU - Felix Nitschke
AU - Shawn C. Burgess
AU - Rachel M. Bailey
PY - 2026
DA - 2026/10/13
JO - Frontiers in Molecular Biosciences
DO - 10.3389/fmolb.2026.1861051
UR - https://doi.org/10.3389/fmolb.2026.1861051
AB - Background: ECHS1 Deficiency (ECHS1D) is a rare neurometabolic disorder caused by loss of function in the mitochondrial enzyme short-chain enoyl-CoA hydratase (ECHS1), leading to developmental delay, dystonia, seizures, and early mortality. Impaired ECHS1 activity disrupts valine catabolism, resulting in accumulation of reactive valine-derived intermediates associated with disease severity, though direct experimental evidence of neuronal toxicity and therapeutic modifiability remains limited. This study aimed to define the consequences of impaired ECHS1 activity, focusing on valine-derived intermediates and their impact on neuronal mitochondrial function. Methods: Wild-type and Echs1-deficient (Echs1D) mouse neuroblastoma (N2A) cells were utilized to investigate effects of patient-relevant valine intermediates S-(2-carboxypropyl)cysteine (SCPC), S-(2-carboxyethyl)cysteine (SCEC), and 2,3-dihydroxy-2-methylbutyric (DHMB) on mitochondrial function, oxidative stress, and cell viability. ECHS1D mice were used to quantify valine intermediates, evaluate pyruvate dehydrogenase complex (PDC) function, and assess seizure susceptibility under typical, excess, or restricted dietary valine intake. Results: In wild-type N2A cells, SCPC exposure induced dose-dependent cell toxicity and impaired mitochondrial respiration, while SCEC and DHMB exerted distinct mitochondrial effects. In contrast, Echs1D N2A cells displayed preserved mitochondrial fitness with premature neuronal differentiation, indicating cell-type-specific metabolic adaptations. ECHS1D mice accumulated SCPC, which was exacerbated by excess dietary valine and associated with reduced pyruvate dehydrogenase complex activity, and worsened seizure susceptibility. Valine restriction initiated during adolescence failed to reduce SCPC or improve seizure outcomes and instead increased SCEC levels. Conclusion: These studies demonstrate that accumulation of ECHS1D-specific valine intermediates, particularly SCPC, contributes to mitochondrial dysfunction and disease severity in ECHS1D. Dietary valine modulation during adolescence showed limited therapeutic benefit and induced broader metabolic perturbations, underscoring the need for improved therapeutic strategies.
SN - 2296-889X
ER -